News Tracy Lessor 9/30/26 Tracy Lessor 9/30/26 Thetis Pharmaceuticals Receives Regulatory Approval in Moldova for Phase 1b Trial of Oral TP-317 in Ulcerative Colitis Read More Tracy Lessor 9/17/26 Tracy Lessor 9/17/26 Thetis Pharmaceuticals Receives $1 Million NIH Commercialization Readiness Pilot Award to Advance Oral TP-317 for Ulcerative Colitis Read More Tracy Lessor 9/8/26 Tracy Lessor 9/8/26 Thetis Pharmaceuticals Announces Patent Grants for TP-317, Extending Protection to Japan and Brazil Read More Tracy Lessor 3/3/26 Tracy Lessor 3/3/26 Thetis Pharmaceuticals Announces U.S. Patent Grant for TP-317, Its First-in-Class Oral BLT1 Agonist for IBD and Oncology Read More Tracy Lessor 2/12/26 Tracy Lessor 2/12/26 Thetis Pharmaceuticals Expands Scientific Advisory Board with Leading Experts in Inflammatory Bowel Disease Read More Tracy Lessor 11/5/25 Tracy Lessor 11/5/25 Thetis Pharmaceuticals Appoints Gerald Nabozny, PhD, as Director, Translational Science Read More Tracy Lessor 10/2/25 Tracy Lessor 10/2/25 Thetis Pharmaceuticals Appoints David N. Cook, PhD, to Board of Managers Read More Tracy Lessor 5/5/25 Tracy Lessor 5/5/25 Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at DDW 2025 Read More Gary Mathias 4/25/25 Gary Mathias 4/25/25 Thetis Pharmaceuticals Presents Preclinical and Clinical Data at AACR Conference in Chicago Read More Dean A. Wetherbee 4/11/25 Dean A. Wetherbee 4/11/25 Thetis Pharmaceuticals Presents Clinical Data at IBD Innovate Conference in NYC Read More Dean A. Wetherbee 2/19/25 Dean A. Wetherbee 2/19/25 Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for BLT1 Agonist TP-317 at ECCO 2025 Read More Dean A. Wetherbee 1/9/25 Dean A. Wetherbee 1/9/25 Thetis Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance Oral BLT1 Agonist into a Phase 1b Trial in Ulcerative Colitis Patients Read More Tracy Lessor 11/14/24 Tracy Lessor 11/14/24 Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and IBD Scientific Advisory Board Read More Dean A. Wetherbee 10/31/24 Dean A. Wetherbee 10/31/24 Thetis Pharmaceuticals Announces Positive Results From Phase 1a Study of TP-317 in Healthy Subjects Read More Dean A. Wetherbee 8/28/24 Dean A. Wetherbee 8/28/24 Thetis Receives $2.3 Million NIH Grant to Develop Immuno-Resolving Therapy for IBD Read More Dean A. Wetherbee 4/4/24 Dean A. Wetherbee 4/4/24 Thetis Pharmaceuticals Commences Phase 1a Clinical Trial with TP-317, an Oral Resolvin E1 Drug Targeting the LTB4-BLT1 Pathway Read More Dean A. Wetherbee 10/4/23 Dean A. Wetherbee 10/4/23 Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Read More Dean A. Wetherbee 7/24/23 Dean A. Wetherbee 7/24/23 Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals Read More Dean A. Wetherbee 7/10/23 Dean A. Wetherbee 7/10/23 John Parkinson, PhD, Immunologist and Biopharma Industry Veteran, Appointed Chief Scientific Officer of Thetis Pharmaceuticals Read More Dean A. Wetherbee 6/13/23 Dean A. Wetherbee 6/13/23 Thetis Forms Australia Subsidiary to Investigate First-in-Class Oral Resolvin E1 Drug (TP-317) for Moderate-to-Severe IBD Read More Older Posts
Tracy Lessor 9/30/26 Tracy Lessor 9/30/26 Thetis Pharmaceuticals Receives Regulatory Approval in Moldova for Phase 1b Trial of Oral TP-317 in Ulcerative Colitis Read More
Tracy Lessor 9/17/26 Tracy Lessor 9/17/26 Thetis Pharmaceuticals Receives $1 Million NIH Commercialization Readiness Pilot Award to Advance Oral TP-317 for Ulcerative Colitis Read More
Tracy Lessor 9/8/26 Tracy Lessor 9/8/26 Thetis Pharmaceuticals Announces Patent Grants for TP-317, Extending Protection to Japan and Brazil Read More
Tracy Lessor 3/3/26 Tracy Lessor 3/3/26 Thetis Pharmaceuticals Announces U.S. Patent Grant for TP-317, Its First-in-Class Oral BLT1 Agonist for IBD and Oncology Read More
Tracy Lessor 2/12/26 Tracy Lessor 2/12/26 Thetis Pharmaceuticals Expands Scientific Advisory Board with Leading Experts in Inflammatory Bowel Disease Read More
Tracy Lessor 11/5/25 Tracy Lessor 11/5/25 Thetis Pharmaceuticals Appoints Gerald Nabozny, PhD, as Director, Translational Science Read More
Tracy Lessor 10/2/25 Tracy Lessor 10/2/25 Thetis Pharmaceuticals Appoints David N. Cook, PhD, to Board of Managers Read More
Tracy Lessor 5/5/25 Tracy Lessor 5/5/25 Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at DDW 2025 Read More
Gary Mathias 4/25/25 Gary Mathias 4/25/25 Thetis Pharmaceuticals Presents Preclinical and Clinical Data at AACR Conference in Chicago Read More
Dean A. Wetherbee 4/11/25 Dean A. Wetherbee 4/11/25 Thetis Pharmaceuticals Presents Clinical Data at IBD Innovate Conference in NYC Read More
Dean A. Wetherbee 2/19/25 Dean A. Wetherbee 2/19/25 Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for BLT1 Agonist TP-317 at ECCO 2025 Read More
Dean A. Wetherbee 1/9/25 Dean A. Wetherbee 1/9/25 Thetis Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance Oral BLT1 Agonist into a Phase 1b Trial in Ulcerative Colitis Patients Read More
Tracy Lessor 11/14/24 Tracy Lessor 11/14/24 Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and IBD Scientific Advisory Board Read More
Dean A. Wetherbee 10/31/24 Dean A. Wetherbee 10/31/24 Thetis Pharmaceuticals Announces Positive Results From Phase 1a Study of TP-317 in Healthy Subjects Read More
Dean A. Wetherbee 8/28/24 Dean A. Wetherbee 8/28/24 Thetis Receives $2.3 Million NIH Grant to Develop Immuno-Resolving Therapy for IBD Read More
Dean A. Wetherbee 4/4/24 Dean A. Wetherbee 4/4/24 Thetis Pharmaceuticals Commences Phase 1a Clinical Trial with TP-317, an Oral Resolvin E1 Drug Targeting the LTB4-BLT1 Pathway Read More
Dean A. Wetherbee 10/4/23 Dean A. Wetherbee 10/4/23 Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Read More
Dean A. Wetherbee 7/24/23 Dean A. Wetherbee 7/24/23 Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals Read More
Dean A. Wetherbee 7/10/23 Dean A. Wetherbee 7/10/23 John Parkinson, PhD, Immunologist and Biopharma Industry Veteran, Appointed Chief Scientific Officer of Thetis Pharmaceuticals Read More
Dean A. Wetherbee 6/13/23 Dean A. Wetherbee 6/13/23 Thetis Forms Australia Subsidiary to Investigate First-in-Class Oral Resolvin E1 Drug (TP-317) for Moderate-to-Severe IBD Read More
